|Articles|December 4, 2018

Cancer's R&D Convergence

Cancer's R&D Convergence will highlight the changing landscape for clinical trials in this therapeutic area based on the promise of the Cancer MoonShot initiative, along with new oncology immunotherapies.

External Link - ACT_Cancer-RD_Convergence.pdf

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Trending on Applied Clinical Trials Online

Cancer's R&D Convergence

Related Content

How Selective Safety Data Collection Could Make Pragmatic Trials Scalable

ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation

Protocol Design Doesn't Fail in the Protocol, It Fails in Transition to Trial

The Data Behind Reducing Trial Burden Without Sacrificing Quality

ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch

Trending on Applied Clinical Trials Online

ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation

NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market

ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch

Protocol Design Doesn't Fail in the Protocol, It Fails in Transition to Trial

ACT Brief: Real-Time Trial Infrastructure Gaps, Built-In Data Security, and AI-Enabled CDMO Value